输血依赖型β地中海贫血的基因治疗:现状与成功的关键标准
本综述讨论了输血依赖型地中海贫血的基因治疗现状、影响疗效的关键标准及早期临床试验的经验教训,并强调了临床开发、生产和监管审批的必要步骤;作者预期基因治疗将很快成为缺乏相容供者患者的治疗选择。
要点
- 基因组测序、干细胞筛选、病毒载体开发、转导和基因编辑技术的进步使离体遗传操作人类干细胞成为可能。
- 综述讨论了输血依赖型地中海贫血的基因治疗现状及影响疗效的关键标准。
- 作者预期基因治疗将很快成为缺乏相容供者进行造血干细胞移植患者的治疗选择。
核心结论
- 作者高度预期基因治疗将很快成为缺乏相容供者进行造血干细胞移植患者的治疗选择,并为β地中海贫血的根治提供替代方案。
研究设计与样本
- 综述:讨论输血依赖型地中海贫血的基因治疗现状、影响疗效的关键标准及早期临床试验的经验教训。
主要发现
- 基因组测序、干细胞筛选、病毒载体开发、转导和基因编辑策略的技术进步允许对人类干细胞进行有效的离体遗传操作,从而产生血红蛋白,为地中海贫血患者带来有意义的临床获益。
关键数值与推荐
- 综述强调了基因治疗临床开发、生产和监管审批所需的必要步骤。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thalassemia is one of the most prevalent monogenic diseases usually caused by quantitative defects in the production of β-globin leading to severe anemia. Technological advances in genome sequencing, stem cell selection, viral vector development, transduction and gene editing strategies now allow for efficient exvivo genetic manipulation of human stem cells that can lead to production of hemoglobin, leading to a meaningful clinical benefit in thalassemia patients. In this review, the status of the gene-therapy approaches available for transfusion dependent thalassemia are discussed, along with the critical criteria that affect efficacy and lessons that have been learned from the early phase clinical trials. Salient steps necessary for the clinical development, manufacturing, and regulatory approvals of gene therapies for thalassemia are also highlighted, so that the potential of these therapies can be realized. It is highly anticipated that gene therapies will soon become a treatment option for patients lacking compatible donors for hematopoietic stem cell transplant and will offer an alternative for definitive treatment of β-thalassemia.
引用
- Soni S. Gene therapies for transfusion dependent β-thalassemia: Current status and critical criteria for success. Am J Hematol. 2020. PMID: 32562290. doi:10.1002/ajh.25909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。